ArQule to Report Third Quarter 2012 Financial Results on November 1, 2012
WOBURN, Mass. -- October 25, 2012
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial
results for the third quarter of 2012 on Thursday, November 1, 2012 at 7:00
a.m. eastern time. The Company will hold a conference call at 9:00 a.m.
eastern time that day to discuss these results.
Conference Call and Webcast
Date: Thursday, November 1, 2012
Time: 9:00 a.m., Eastern Time
Conference Call Numbers
Domestic (toll free): (877) 868-1831
International: (914) 495-8595
A replay of the conference call will be available beginning on November 1,
2012 approximately two hours after the call’s completion for seven days and
can be accessed by dialing toll-free (855) 859-2056 and outside the U.S. (404)
537-3406. The confirmation code for archived calls is 53861797.
ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline
consists of ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and
ARQ 736, designed to inhibit the RAF kinases. ArQule’s current discovery
efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are
focused on the identification of novel kinase inhibitors that are potent,
selective and do not compete with ATP (adenosine triphosphate) for binding to
William B. Boni, 781-994-0300
VP, Investor Relations/ Corp. Communications
Press spacebar to pause and continue. Press esc to stop.